HC Wainwright Adjusts FY2026 Earnings Estimate for Corcept Therapeutics

On October 31st, analysts from HC Wainwright announced an increase in their earnings per share (EPS) estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT). According to analyst S. Ramakanth, the expected EPS for the biotechnology firm in FY2026 has been raised from $3.55 to $3.67. HC Wainwright maintains a "Buy" rating on the stock and has set a price target of $80.00.

The current consensus for Corcept Therapeutics' full-year earnings stands at $1.12 per share. The firm also provided projections for future earnings, estimating EPS of $4.78 for FY2027 and $5.64 for FY2028.

Recent Analyst Insights

Several other analysts have also shared their views on the stock recently. Sandler O’Neill reaffirmed a "Buy" rating on Corcept Therapeutics on October 18th, while Truist Financial raised their price target from $65.00 to $76.00 and also maintained a "Buy" rating on September 30th.

StockNews.com upgraded Corcept Therapeutics from a "Buy" to a "Strong-Buy" rating on Thursday. Additionally, Canaccord Genuity Group restated their "Buy" rating with a price target of $38.00 on July 30th. Piper Sandler also revised their price target upward, changing it from $38.00 to $67.00 with an "Overweight" rating on September 18th. This consolidated analyst sentiment shows strong confidence in the firm, with five analysts rating it as "Buy" and one as "Strong-Buy." Currently, the average rating for Corcept is "Buy" with a consensus price target of $65.25.

Stock Performance of Corcept Therapeutics

On Friday, Corcept Therapeutics shares opened at $47.62. The company has a market capitalization of $4.98 billion and has shown significant trading performance, with P/E ratios at 37.79. The stock's price has fluctuated between a low of $20.84 and a high of $50.07 over the past year.

Recently, Corcept Therapeutics reported its quarterly earnings on October 30th, revealing an EPS of $0.41, surpassing analysts' expectations of $0.27. Revenue for the quarter was reported at $182.55 million, significantly higher than the expected $171.97 million. Year-over-year, the company's revenue grew by 47.7%, up from $0.28 EPS in the same quarter last year.

Institutional Investments in Corcept

Institutional investors have been active in buying and selling shares of Corcept Therapeutics. Recently, Capital Performance Advisors LLP bought a new stake in the company during the third quarter. Park Place Capital Corp and Atwood & Palmer Inc. also made new purchases. Notably, hedge funds and institutional investors hold approximately 93.61% of the company's shares.

Insider Transactions

In corporate governance, insider Gary Charles Robb sold 11,000 shares of Corcept stock on October 1st at an average price of $46.28, totaling $509,080. Following this sale, Robb retains ownership of 22,772 shares. Additionally, in a prior transaction on September 3rd, insider William Guyer sold 10,000 shares at an average of $35.30. The total insider transactions in the last 90 days accounted for 24,101 shares worth $972,817, with insiders now holding 20.50% of the company's stock.

About Corcept Therapeutics

Corcept Therapeutics is focused on discovering and developing treatments for severe disorders, including endocrinologic, oncologic, metabolic, and neurologic conditions. Its primary product, Korlym, is used to treat hyperglycemia related to hypercortisolism in adult patients with endogenous Cushing's syndrome, particularly those who have type 2 diabetes or glucose intolerance and are not suitable for surgery.

earnings, analysis, stocks